Advertisement
Speaking at the press conference, Dr.Srinubabu G, Managing Director of OMICS International Inc. said that the conference and exhibition is expected to draw participation of over 300 from different parts of the globe.
Advertisement
Adding further he stated that OMICS did the first conference on the subject in Europe, second in United States and this third one is being organised in Hyderabad. Because, there are chances that Hyderabad can become the Capital for Biosimilars, informed Dr. Srinubabu Gedela.
The global market for Biosimilars is expcted to be 20 Billion US Dollars in the year 2015. India and China would have around 70% of the global Biosimilars market because in these countries manufacturing and R&D costs are very less, he said. And added that we expect, Hyderabad to capture more than 50% of this global market. Infact, Hyderabad has all the required aspects like knowledge, scientists base, infrastructure and market to become global leader. The timing of this conference is even more important as 100s of patents are expiring in the year 2015.
Hyderabad
These participants include entrepreneurs from Pharma, Biotech, CMOs, CROs, Research Institutions, Investors and Industry stakeholders, academicians, government and the non-government professionals who would discuss critical issues pertaining to biosimilars and biological drugs to find an acceptable solution to this growing demand for lifesaving generic medicines. Experts in the field of Biosimilars including Dr. Mrs. Kaiser Jamil, Director - Centre for Biotechnology and Bioinformatics, Jawaharlal Nehru Institute of Advanced Studies (JNIAS), India; Mr. Ranajit Sen, CEO, Graphene Med Resource LLP; Dr. Rama Krishna Bangaru, Sr. Vice President-Biopharmaceutics, Mylan Laboratories, India; Dr. Murali Bukkapatnam, Managing Director, GDH Workforce Pvt. Ltd. were also present at the press meet held at NKM Grand Hotel here at Hyderabad.
The conference will witness Keynote lectures, Workshops, Discussions, Concurrent Sessions, Oral and Poster presentations. Thisconference will gather experts in biosimilar development, manufacturing and marketing from all over the world. Some of the speakers include Krishna Menon of Cellceutix Corporation, USA; Daniel Galbraith of Bio Outsource Ltd, UK; Rodeina Challand of PRA Health Sciences, UK and Kamali Chance of Quintiles, UK. The attending delegates include Editorial Board Members of related OMICS Group Journals.
The Conference Highlights include: Challenges and Regulatory Approach for Biosimilars; Emerging Biosimilars in Therapeutics; Clinical Studies and Clinician’s Prospects for Biosimilars; Globalization of Biosimilars; Biosimilars Innovator Pharmaceutical Products; Analytical Strategies; Bioequivalence Assessment; BCS & IVIVC Based Biowaivers; Plant Produced Biosimilar Products and Pharmacovigilance and its Challenges.
Biowaivers is an exemption granted to the biopharmaceutical companies to a particular bioequivalent product. The patent expirations of generics have given a gateway to Biosimilars into the Global Pharmaceutical Economy for the past few years.
Biosimilars is a biopharmaceutical drug designed to have active properties similar to the one that has previously been licensed. Biosimilars or Biologics are biological medical products made or derived from the active drug substance of a living organism by recombination of DNA or Controlled gene expression methods.
Biosimilar medicines are follow-on versions of original biological medicines. They are independently developed after the patent protecting the original product has expired. Biosimilar medicines are intended to have the same mechanism of action as the original biological medicines, and are designed to treat the same diseases as the innovator’s product. The name, appearance and packaging of a biosimilar medicine differ to those of the biological reference medicine.
Biosimilars-2014 is collaborated with DPA (Doctor of Pharmacy Association), PAAi (Patent Agent Association), Association of Biotechnology and Pharmacy, Association of Pharmacy Professionals, BioFocus Research Center and Association of Pharmaceutical Teachers in India.
Two Workshops are being organized by Dr. Shivraj Dasari, CSO of SLS Cell Culture Technologies Pvt. Ltd and Dr. Rajiv Dahiya, President, Association of Pharmacy Professionals at this scientific conference.This event is expected to boost the participant’s industry knowledge and enhance relationships by networking industrialists and academic leaders.
OMICS and TiE jointly conduct a session on Investment opportunities in Biosimilars and Biologics in Hyderabad. Mr. Murali Bhukkapatnam, Managing Director GDH Workforce Pvt. Ltd. would be one of the keynote speakers. This would be a part of the 3rd International conference and Exhibition on Biowaivers, Biologics and Biosimilars.
The criteria required in filing of biological drugs will be discussed by popular agencies and their representatives in this meeting. Biosimilars trials and special case reports will be presented to denote the purpose and clinical data requirements for the future growth of Biowaivers, Biologics and Biosimilars.
Biosimilars-2014 will provide an excellent global opportunity to the scientists, partners and pharma leaders from Biopharmaceutical and Biotechnology industries to innovate and to explore the strategic market of Biologics and Biosimilars.
